2023年加拿大炎症性肠病的影响:特殊人群-老年ibd

Seth R Shaffer, M Ellen Kuenzig, Joseph W Windsor, Alain Bitton, Jennifer L Jones, Kate Lee, Sanjay K Murthy, Laura E Targownik, Juan-Nicolás Peña-Sánchez, Noelle Rohatinsky, Sara Ghandeharian, Parul Tandon, Joëlle St-Pierre, Navneet Natt, Tal Davis, Jake Weinstein, James H B Im, Eric I Benchimol, Gilaad G Kaplan, Quinn Goddard, Julia Gorospe, Maxime Bergevin, Ken Silver, Dawna Bowles, Margaret Stewart, Marsha Pearlstein, Elizabeth H Dawson, Charles N Bernstein
{"title":"2023年加拿大炎症性肠病的影响:特殊人群-老年ibd","authors":"Seth R Shaffer,&nbsp;M Ellen Kuenzig,&nbsp;Joseph W Windsor,&nbsp;Alain Bitton,&nbsp;Jennifer L Jones,&nbsp;Kate Lee,&nbsp;Sanjay K Murthy,&nbsp;Laura E Targownik,&nbsp;Juan-Nicolás Peña-Sánchez,&nbsp;Noelle Rohatinsky,&nbsp;Sara Ghandeharian,&nbsp;Parul Tandon,&nbsp;Joëlle St-Pierre,&nbsp;Navneet Natt,&nbsp;Tal Davis,&nbsp;Jake Weinstein,&nbsp;James H B Im,&nbsp;Eric I Benchimol,&nbsp;Gilaad G Kaplan,&nbsp;Quinn Goddard,&nbsp;Julia Gorospe,&nbsp;Maxime Bergevin,&nbsp;Ken Silver,&nbsp;Dawna Bowles,&nbsp;Margaret Stewart,&nbsp;Marsha Pearlstein,&nbsp;Elizabeth H Dawson,&nbsp;Charles N Bernstein","doi":"10.1093/jcag/gwad013","DOIUrl":null,"url":null,"abstract":"<p><p>Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn's disease; perianal disease is less common. Other common diagnoses in the elderly must also be considered when they initially present to a healthcare provider. Treatment of the elderly is similar to younger persons with IBD, though considerations of the increased risk of infections and malignancy must be considered when using immune modulating drugs. Whether anti-TNF therapies increase the risk of infections is not definitive, though newer biologics, including vedolizumab and ustekinumab, are thought to be safer with lower risk of adverse events. Polypharmacy and frailty are other considerations in the elderly when choosing a treatment, as frailty is associated with worse outcomes. Costs for IBD-related hospitalizations are higher in the elderly compared with younger persons. When elderly persons with IBD are cared for by a gastroenterologist, their outcomes tend to be better. However, as elderly persons with IBD continue to age, they may not have access to the same care as younger people with IBD due to deficiencies in their ability to use or access technology.</p>","PeriodicalId":17263,"journal":{"name":"Journal of the Canadian Association of Gastroenterology","volume":"6 Suppl 2","pages":"S45-S54"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478801/pdf/","citationCount":"0","resultStr":"{\"title\":\"The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.\",\"authors\":\"Seth R Shaffer,&nbsp;M Ellen Kuenzig,&nbsp;Joseph W Windsor,&nbsp;Alain Bitton,&nbsp;Jennifer L Jones,&nbsp;Kate Lee,&nbsp;Sanjay K Murthy,&nbsp;Laura E Targownik,&nbsp;Juan-Nicolás Peña-Sánchez,&nbsp;Noelle Rohatinsky,&nbsp;Sara Ghandeharian,&nbsp;Parul Tandon,&nbsp;Joëlle St-Pierre,&nbsp;Navneet Natt,&nbsp;Tal Davis,&nbsp;Jake Weinstein,&nbsp;James H B Im,&nbsp;Eric I Benchimol,&nbsp;Gilaad G Kaplan,&nbsp;Quinn Goddard,&nbsp;Julia Gorospe,&nbsp;Maxime Bergevin,&nbsp;Ken Silver,&nbsp;Dawna Bowles,&nbsp;Margaret Stewart,&nbsp;Marsha Pearlstein,&nbsp;Elizabeth H Dawson,&nbsp;Charles N Bernstein\",\"doi\":\"10.1093/jcag/gwad013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn's disease; perianal disease is less common. Other common diagnoses in the elderly must also be considered when they initially present to a healthcare provider. Treatment of the elderly is similar to younger persons with IBD, though considerations of the increased risk of infections and malignancy must be considered when using immune modulating drugs. Whether anti-TNF therapies increase the risk of infections is not definitive, though newer biologics, including vedolizumab and ustekinumab, are thought to be safer with lower risk of adverse events. Polypharmacy and frailty are other considerations in the elderly when choosing a treatment, as frailty is associated with worse outcomes. Costs for IBD-related hospitalizations are higher in the elderly compared with younger persons. When elderly persons with IBD are cared for by a gastroenterologist, their outcomes tend to be better. However, as elderly persons with IBD continue to age, they may not have access to the same care as younger people with IBD due to deficiencies in their ability to use or access technology.</p>\",\"PeriodicalId\":17263,\"journal\":{\"name\":\"Journal of the Canadian Association of Gastroenterology\",\"volume\":\"6 Suppl 2\",\"pages\":\"S45-S54\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478801/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Canadian Association of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jcag/gwad013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Canadian Association of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jcag/gwad013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

大约每88名老年人中就有1人患有炎症性肠病(IBD),预计这一数字在未来还会增加。溃疡性结肠炎患者更易患左侧疾病,克罗恩病患者更易患孤立性结肠疾病;肛周疾病不太常见。其他常见的诊断在老年人也必须考虑当他们最初呈现给医疗保健提供者。老年IBD患者的治疗方法与年轻IBD患者相似,但在使用免疫调节药物时必须考虑到感染和恶性肿瘤风险的增加。抗肿瘤坏死因子治疗是否会增加感染风险尚不明确,尽管包括vedolizumab和ustekinumab在内的新生物制剂被认为更安全,不良事件风险更低。在选择治疗方法时,多种药物和虚弱是老年人的其他考虑因素,因为虚弱与较差的结果相关。与年轻人相比,老年人ibd相关的住院费用更高。当患有IBD的老年人由胃肠病学家照顾时,他们的结果往往会更好。然而,随着老年IBD患者不断变老,由于缺乏使用或获取技术的能力,他们可能无法获得与年轻IBD患者相同的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The 2023 Impact of Inflammatory Bowel Disease in Canada: Special Populations-IBD in Seniors.

Approximately one out of every 88 seniors has inflammatory bowel disease (IBD), and this is expected to increase in the future. They are more likely to have left-sided disease in ulcerative colitis, and isolated colonic disease in Crohn's disease; perianal disease is less common. Other common diagnoses in the elderly must also be considered when they initially present to a healthcare provider. Treatment of the elderly is similar to younger persons with IBD, though considerations of the increased risk of infections and malignancy must be considered when using immune modulating drugs. Whether anti-TNF therapies increase the risk of infections is not definitive, though newer biologics, including vedolizumab and ustekinumab, are thought to be safer with lower risk of adverse events. Polypharmacy and frailty are other considerations in the elderly when choosing a treatment, as frailty is associated with worse outcomes. Costs for IBD-related hospitalizations are higher in the elderly compared with younger persons. When elderly persons with IBD are cared for by a gastroenterologist, their outcomes tend to be better. However, as elderly persons with IBD continue to age, they may not have access to the same care as younger people with IBD due to deficiencies in their ability to use or access technology.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
296
审稿时长
10 weeks
期刊最新文献
Response from the Canadian Children Inflammatory Bowel Disease Network to the US Food and Drug Administration Draft Guidance for Industry on pediatric inflammatory bowel disease: developing drugs for treatment. A Year in Review: JCAG's Inaugural Editorial Fellowship. Clinical features, management, and complications of paediatric button battery ingestions in Canada: an active surveillance study using surveys of Canadian paediatricians and paediatric subspecialists. Canadian female perspectives on training in the boys club: advanced therapeutic endoscopy. Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1